References
- 1. A. Lacy and R. O’Kennedy, Studies on coumarins and coumarin-related compounds to determine their therapeutic role in the treatment of cancer, Cur. Pharm. Des. 10 (2004) 3797-3811; DOI: 10.2174/1381612043382693.
- 2. M. E. Marshall, M. Ryles, K. Butler and L. Weiss, Treatment of advanced renal cell carcinoma (RCC) with coumarin and cimetidine: longterm follow-up of patients treated on a phase I trial, J. Cancer Res. Clin. Oncol. 120 (1994) 535-538.
- 3. U. S. Weber, B. Steff en and C. P. Siegers, Antitumour-activities of coumarin, 7-hydroxycoumarin and its glucuronide in several human tumour cell lines, Res. Commun. Mol. Pathol. Pharmacol. 99 (1998) 193-206.
- 4. M. A. Velasco-Velazquez, J. Agramonte-Hevia, D. Barrera, A. Jimenez-Orozco, M. J. Garcia-Mondragon, N. Mendoza-Patino, A. Landa and J. Mandoki, 4-Hydroxycoumarin disorganizes the actin cytoskeleton in B16-F10 melanoma cells but not in B82 fibroblasts, decreasing their adhesion to extracellular matrix proteins and motility, Cancer Le_ . 198 (2003) 179-186; DOI: 10.1016/S0304-3835(03)00333-1.
- 5. S. Stanchev, G. Momekov, F. Jensen and I. Manolov, Synthesis, computational study and cytotoxic activity of new 4-hydroxycoumarin derivatives, Eur. J. Med. Chem. 43 (2008) 694-706; DOI: 10.1016/j.ejmech.2007.05.005.
- 6. J. L. Mohler, L. G. Gomella, E. D. Crawford, L. M. Glode, C. D. Zippe, W. R. Fair and M. E. Marshall, Phase II evaluation of coumarin (1,2-benzopyrone) in metastatic prostatic carcinoma, Prostate 20 (1992) 123-131.
- 7. F. H. Dexeus, C. J. Logothetis, A. Sella, K. Fitz, R. Amato, J. M. Reuben and N. Dozier, Phase II study of coumarin and cimetidine in patients with metastatic renal-cell carcinoma, J. Clin. Oncol. 8 (1990) 325-329.
- 8. D. Cooke, Studies on the Mode of Action of Coumarins (Coumarin, 6-Hydroxycoumarin, 7-Hydroxycoumarin and Esculetin) at a Cellular Level, Ph. D. Thesis, Dublin City University, Dublin, 1999; h_ p:// doras.dcu.ie/18438/1/Deirdre_A_Cooke.pdf; last access date March 10, 2014.
- 9. F. Jimenez-Orozco, J. S. Lopez-Gonzalez, A. Nieto-Rodriguez, M. A. Velasco-Velazquez, J. A. Molina- Guarneros, N. Mendoza-Patino, M. J. Garica-Mondragon, P. Elizalde-Galvan, F. Leon-Cedeno and J. J. Mandoki, Decrease of cyclin D1 in the human lung adenocarcinoma cell line A-427 by 7-hydroxycoumarin, Lung Cancer 34 (2001) 185-194.
- 10. M. A. Musa, J. S. Cooperwood and M. O. F. Khan, A review of cumarin derivatives in pharmacotherapy of breast cancer, Cur. Med. Chem. 15 (2008) 2664-2679; DOI: 10.2174/092986708786242877.
- 11. H. A. Assi, K. E. Khoury, H. Dbouk, L. E. Khalil, T. H. Mouhieddine and N. S. El Saghir, Epidemiology and prognosis of breast cancer in young women, J. Thorac. Dis. 5 (2013) S2-S8; DOI: 10.3978/j. issn.2072-1439.2013.05.24.
- 12. Y-H. Hsiao, M-C. Chou, C. Flower, J. T. Mason and Y-G. Man, Breast cancer heterogeneity: mechanisms, proofs, and implications, J. Cancer 1 (2010) 6-13; DOI: 10.7150/jca.1.6.
- 13. Y. G. Man and H. E. Nieburgs, A subset of cell clusters with malignant features in morphologically normal and hyperplastic breast tissues, Cancer Detect. Prev. 30 (2006) 239-247; DOI: 10.1016/j. cdp.2006.04.006.
- 14. P. Clezardin, Therapeutic targets for bone metastases in breast cancer, Breast Cancer Res. 13 (2011) 207-215; DOI: 10.1186/bcr2835.
- 15. M. C. Ravnan, S. L. Ravnan and M. P. Walberg, Metastatic breast cancer: a review of current and novel pharmacotherapy, Formulary 46 (2011) 130-146.
- 16. F. Cardoso, E. Senkus-Kone_ a, L. Fallowfi eld, A. Costa and M. Castigilone, Locally recurrent or metastatic breast cancer: ESMO Clinical practice guidelines for diagnosis, treatment and followup, Ann. Oncol. 21 (2010) v15-v19; DOI: 10.1093/annonc/mdq160.
- 17. O. Pagani, E. Senkus, W. Wood, M. Colleoni, T. Cufer, S. Kyriakides, A. Costa, E. P. Winer and F. Cardoso, International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J. Natl. Cancer Inst. 102 (2010) 456-463; DOI: 10.1093/jnci/djq029.18.
- 18. A. Jashari, F. Imeri, L. Ballazhi, A. Shabani, B. Mikhova, G. Drager, E. Popovski and A. Huwiler, Synthesis and cellular characterization of novel isoxazolo- and thiazolohydrazinyldiene-chroman-2,4-diones on cancer and non-cancer cell growth and death, Bioorg. Med. Chem. 22 (2014) 2655-2661; DOI: 10.1016/j.bmc.2014.03.026.19.K.
- 19. K. Tabakovic, I. Tabakovic, M. Trkovnik and N. Trinajstic, Chemistry of coumarins. Nucleophilic substitutions of 4-chloro-3-nitrocoumarin with hard and so_ nucleophiles, Liebigs Ann. Chem. 11 (1983) 1901-1909; DOI: 10.1002/jlac.198319831105.
- 20. M. M. Ramla, M. A. Omar, A. M. M. El-Khamry and H. L. El-Diwan, Synthesis and antitumour activity of 1-substituted-2-methyl-5-nitrobenzimidazoles, Bioorg. Med. Chem. 14 (2006) 7324-7332; DOI: 10.1016/j.bmc.2006.06.033.
- 21. E. Gulsory and N. U. Guzeldemirci, Synthesis and primary cytotoxicity evaluation of new imidazo[ 2,1-b]thiazole derivatives, Eur. J. Med. Chem. 42 (2007) 320-326; DOI: 10.1016/j.ejmech. 2006.10.012.
- 22. M. J. Choi, E. S. No, D. A. Thorat, J. W. Jang, H. Yang, J. Lee, H. Choo, S. J. Kim, C. S. Lee, S. Y. Ko, J. Lee, G. Nam and A. N. Pae, Synthesis and biological evaluation of aryloxazole derivatives as antimitotic and vascular-disrupting agents for cancer therapy, J. Med. Chem. 56 (2013) 9008-9018; DOI: 10.1021/jm400840p.
- 23. P. Poma, M. Notarbartolo, M. Labbozze_ a, A. Maurici, V. Carina, Alaimo, M. Rizzi, D. Simoni and N. D’Alessandro, The antitumour activities of curcumin and of its isoxazole analogue are not affected by multiple gene expression changes in an MDR model of the MCF-7 breast cancer cell line: analysis of the possible molecular basis, Int. J. Mol. Med. 20 (2007) 329-335; DOI: 10.3892/ ij mm.20.3.329.
- 24. M. S. Al-Said, M. S. Bashandy, S. I. Al-qasoumi and M. M. Ghorab, Anti-breast cancer activity of some novel 1,2-dihydropyridine, thiophene and thiazole derivatives, Eur. J. Med. Chem. 46 (2011) 137-141; DOI: 10.1016/j.ejmech.2010.10.024.
- 25. M. I. Soares, A. F. Brito, M. Laranjo, A. M. Abrantes, M. F. Botelho, J. A. Paixao, A. M. Beja, M. R. Silva, E. Pinho and T. M. Melo, Chiral 6-hydroxymethyl-1H,3H-pyrrolo[1,2-c]thiazoles: novel antitumour DNA monoalkylating agents, Eur. J. Med. Chem. 45 (2010) 4676-4681; DOI: 10.1016/j.ejmech. 2010.07.029.
- 26. P. Chene, C. Garcia-Echeverria, M. R. Jensen, C. Quadt, T. Radimerski and J. Schoepfer, Isoxasole compound for the treatment of cancer, Patent WO 2009047323 A2, 16 April 2009.
- 27. Y. Kang, P. M. Siegel, W. Shu, M. Drobnjak, S. M. Kakonen, C. Cordon-Cardo, T. A. Guise and J. Massague, A multigenic program mediating breast cancer metastasis to bone, Cancer Cell 3 (2003) 537-549; DOI: 10.1016/S1535-6108(03)00132-6.
- 28. A. J. Minn, G. P. Gupta, P. M. Siegel, P. D. Bos, W. P. Shu, D. D. Giri, A. Viale, A. B. Olshen, W. L. Gerald and J. Massague, Genes that mediate breast cancer metastasis to lung, Nature 436 (2005) 518-524; DOI: 10.1038/nature03799.29.
- 29. A. Jashari, E. Hey-Hawkins, B. Mikhova, G. Draeger and E. Popovski, An improved synthesis of 4-chlorocoumarin-3-sulfonyl chloride and its reactions with diff erent bidentae nucleophiles to give pyrido[1’,2’:2,3]- and thiazino[3’,2’:2,3]-1,2,4-thiadiazino[6,5-c]Benzopyran-6-one 7,7-dioxides, Molecules 12 (2007) 2017-2028; DOI: 10.3390/12082017.
- 30. A. Jashari, E. Popovski, B. Mikhova, R. P. Nikolova and B. L. Shivachev, 3-[2-(5-tert-butyl-1,2-oxazol-3-yl)hydrazinylidene] chroman-2,4-dione, Acta Crystalogr. E 69 (2013) o258; DOI: 10.1107/ S1600536813000858.